Galderma presented new phase III data from the READY-4 clinical trial at the American Society for Dermatologic Surgery (ASDS) 2024 Annual Meeting last week. The data demonstrates the long-term safety of RelabotulinumtoxinA (RelfydessTM) for frown lines and crow’s feet after repeated injections.
The READY-4 study met its primary and secondary endpoints, with less than one in five participants experiencing treatment-related treatment-emergent adverse events (TEAEs), and all events deem mild or moderate.
Efficacy and patient satisfaction were also maintained across multiple treatments.
RelabotulinumtoxinA is the first and only ready-to-use liquid neuromodulator created with PEARLTM Technology that is designated to preserve molecule integrity to deliver a highly active, innovative, complex-free molecule.
According to previously released data from the READY clinical trial, up to 30% of patients see effects from day one and up to 75% of patients maintain improvements for six months for frown lines and crow’s feet when treated with RelabotulinumtoxinA.
